Depression and anxiety rank among the top global health challenges. Since 1990, these disorders have surged, placing them in ...

A new systematic review from Utrecht University in the Netherlands explores the potential of minor cannabinoids in treating ...

Efforts have been made in recent years to clarify the value of exercise as an adjunctive or independent treatment for major ...

Seasonal Affective Disorder (SAD) affects millions of Americans, and cases usually start to rise in late fall or early winter ...

A TSX-listed global cannabis company behind the TWEED brand continued its progress towards profitability in Q2 fiscal 2025.

de Filippis, R. and Al Foysal, A. (2024) Case Report: The Role of Monoamine Oxidase Inhibitors in Treating Resistant Depression. Open Access Library Journal, 11, 1-12. doi: 10.4236/oalib.1112369 .

The global major depressive disorder (MDD) treatment market is expected to experience steady growth, projected to develop at ...

Psychedelics like psilocybin, MDMA, and ketamine are emerging as promising therapeutic tools for mental health issues. Here's ...

Cybin (TSE:CYBN) has released an update. Cybin Inc. is set to unveil promising 12-month Phase 2 data for CYB003 in treating Major Depressive ...

Cybin (TSE:CYBN) has released an update. Cybin Inc. is set to present promising 12-month data from its Phase 2 study of CYB003, aimed at ...

The Horizon 3.0 TMS Therapy System is a computerized, noninvasive medical device that directs electrical currents at different regions of the cerebral cortex.

The firm expects to report its 12-month phase 2 data next week, with topline results from a phase 3 trial anticipated in 2026 ...